Breast cancers of all three subtypes were represented, nine hormone receptor-expressing (HR+), nine triple-negative breast cancer (TNBC) and seven HER2 amplified or overexpressed (HER2+) (Table S1). This evidence concerns the gene HR and triple-negative breast carcinoma.